Biotechnology - , ,
Mycroft Bioanalytics conducts precision medicine analytics to provide actionable information about pain, the largest health condition in the United States. These analytics include profiles that determine risk of opioid use disorder; opioid and non-opioid response; risk of conditions including venous thromboembolism, fibromyalgia, substance use disorders, TMJD; and others. To complement the algorithm research and development, Mycroft owns and manages the world's largest Biobank in chronic pain, with over 116,000 DNA samples and 29 billion clinical data points. The clinical utility and validity of Mycroft's predictive analyses have been scientifically validated in peer-reviewed journals, including Science, Human Molecular Genetics, and Pain.
Gmail
Google AdSense
Mobile Friendly
Google Cloud Hosting